We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cirmtuzumab

News List

Oncternal gets FDA orphan drug designations for cirmtuzumab to treat MCL and CLL pharmaceutical-business-review
July 06, 2020
Oncternal Therapeutics announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designations of cirmtuzumab for treatment of mantle cell lymphoma (MCL) and for treatment of chronic lymphocytic leukaemia ...
Oncternal Announces First Patient Dosed in Cirmtuzumab, Paclitaxel Trial americanpharmaceuticalreview
September 13, 2018
Oncternal Therapeutics announced the first patient has been dosed in a Phase 1b study of cirmtuzumab, an anti-ROR1 monoclonal, in combination with standard-of-care chemotherapy drug paclitaxel in patients with HER2/neu negative metastatic or locally advan